Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ANO2 | Q9NQ90 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024605 | 0.89 | NAMPT (0.47) | ANO1MAPTSMN1; SMN2TP53FLT1 | |
| SCHEMBL4019850 | 0.84 | TP53 (0.47) | MAPTSMN1; SMN2TP53ALDH1A1NAMPT | |
| SCHEMBL4023076 | 0.84 | RAB9A (0.43) | MAPTSMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL4018794 | 0.83 | MAPT (0.48) | ANO1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL4021305 | 0.82 | BLM (0.44) | MAPTSMN1; SMN2TP53FLT1KDR | |
| SCHEMBL4019844 | 0.74 | KDR (0.51) | HIF1AEPAS1MAPTALDH1A1FLT1 | |
| SCHEMBL20353920 | 0.74 | ANO1 (0.65) | ANO1TLR2MAPTSMN1; SMN2TP53 | |
| SCHEMBL12176745 | 0.73 | ALOX15 (0.56) | MAPTSMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL4136619 | 0.72 | ANO1 (1.00) | ANO1MAPTSMN1; SMN2TP53ANO2 | |
| SCHEMBL4015571 | 0.70 | L3MBTL1 (0.65) | HIF1AEPAS1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1602647-A1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | FLT4, FLT1, KDR | ANO1 2265/4885HIF1A 611/4885EPAS1 218/4885 |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | FLT1, FLT4, PYM1 | ANO1 784/4885HIF1A 474/4885EPAS1 538/4885 |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | FLT1, PYM1, FLT4 | ANO1 861/4885HIF1A 757/4885EPAS1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.